Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma
Baojiang Liu,Song Gao,Jianhai Guo,Fuxin Kou,Shaoxing Liu,Xin Zhang,Aiwei Feng,Xiaodong Wang,Guang Cao,Hui Chen,Peng Liu,Haifeng Xu,Qinzong Gao,Renjie Yang,Liang Xu,Xu Zhu
DOI: https://doi.org/10.2147/jhc.s452120
2024-03-05
Journal of Hepatocellular Carcinoma
Abstract:Baojiang Liu, &ast Song Gao, &ast Jianhai Guo, Fuxin Kou, Shaoxing Liu, Xin Zhang, Aiwei Feng, Xiaodong Wang, Guang Cao, Hui Chen, Peng Liu, Haifeng Xu, Qinzong Gao, Renjie Yang, Liang Xu, Xu Zhu Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China, Tel + 86-10-8819-6059, Email Purpose: Recently, hepatic arterial infusion chemotherapy (HAIC) has also gained popularity for hepatocellular carcinoma (HCC). Several studies have compared HAIC and Transarterial chemoembolization (TACE). However, comparisons between TACE plus HAIC and HAIC are rarely reported. Here, we evaluated the performance of HepaSphere DEB-TACE combined with HAIC (Hepa-HAIC) compared to HAIC in patients with advanced HCC. Patients and Methods: In this retrospective study, we enrolled 167 patients diagnosed with advanced HCC and treated at Peking University Cancer Hospital from May 2018 to May 2022. The cohort comprised 74 patients who received HepaSphere DEB-TACE combined with HAIC-FOLFOX (Hepa-HAIC) and 93 patients who received HAIC-FOLFOX. Over 60% of patients received prior treatments. To avoid selection bias, propensity score matching was applied to the efficacy and safety analyses. The primary endpoints are progression-free survival (PFS) and overall survival (OS); the secondary endpoints include objective response rate (ORR), disease control rate (DCR), and safety. Results: Propensity-matching yielded 48 pairs, and group baselines were almost equal after matching. Median PFS and median OS were both higher in the matched Hepa-HAIC cohort (median PFS: 8.9 vs 5.8 months, p = 0.035; median OS: 22.4 vs 9.5 months, p = 0.027), which was consistent with pre-matching analysis. The ORR in the Hepa-HAIC and HAIC cohorts was 75.0% and 37.5%, respectively; the DCR was 93.8% after Hepa-HAIC and 81.3% after HAIC. There was no treatment-related death. Grade 3– 4 ALT elevation was more frequent in the Hepa-HAIC group (33.3% vs 8.3%, p = 0.003), while vomiting was more frequent in the HAIC group (29.2% vs 12.5%, p = 0.084). Conclusion: The Hepa-HAIC group is superior to the HAIC group in metrics of PFS, OS, ORR, and DCR, which indicates the combination of HepaSphere DEB-TACE and HAIC may lead to improved outcomes with a comparable safety profile in advanced HCC. Keywords: transarterial chemoembolization, advanced hepatocellular carcinoma, hepatic arterial infusion chemotherapy, propensity score matching Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related deaths worldwide. 1 More than 70% of patients with HCC are diagnosed with advanced disease, which is a challenging clinical scenario. 2 Transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) are two widely used locoregional therapies for the treatment of advanced HCC. 3 Atezolizumab and bevacizumab are the preferred first-line treatments for advanced HCC, with a median overall survival (OS) of 19.2 months and a median progression-free survival (PFS) of 6.9 months. 4 Lenvatinib is an optional first-line treatment for unresectable HCC, with a median survival time of 13.6 months. 5 Treatment with regorafenib and cabozantinib is a second-line option for patients with HCC, with a median OS of 10.2–10.6 months and a significantly longer OS than with placebo. 6,7 As all currently approved and recommended clinical trials of second-line agents have been conducted in populations after progression on first-line sorafenib, treatment selection following resistance to first-line ICI and targeted therapy remains a challenge. The choice of second-line therapy after first-line (ICI combined with targeted treatment) is empirical and largely depends on drug safety, patient comorbidities, physician and patient preferences, and local reimbursement policies.In advanced HCC, there is an urgent need for additional treatment options for HCC that has already received targeted treatment and immunotherapy. DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) and HAIC (Hepatic Arterial Infusion Chemotherapy) are common treatments for unresectable HCC; the efficacy is less certain for HAIC alone or DEB-TACE combined with HAIC. DEB-TACE is a minimally invasive procedure that delivers chemotherapy drug -Abstract Truncated-
oncology